KAI 12L | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

9,042 results for “KAI 12L”

Trials

View all 5616 →

Clinical Validation and Safety of the AC 12L ECG System Against a Standard of Care 12-Lead ECG (AC 12L ECG)

200 participants · First posted Nov 15, 2022

Safety and Efficacy Study of KAI-9803 to Treat Subjects With ST Elevation Myocardial Infarction [Heart Attack]

1,180 participants · First posted Nov 5, 2008

Active, not recruiting

Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity

306 participants · First posted Mar 27, 2026

Drugs

View all 1171 →

Investigational

KAI-1678

Investigational

KAI-1455

Organizations

View all 70 →

Kai Pharmaceuticals, Inc.

United States

KAI Medical, Inc.

United States

KAI YUEN PHARMACEUTICAL LIMITED

Hong Kong, China

News

View all 2185 →

AliveCor Receives CE Mark for Portable 12-Lead ECG System with AI-Powered Cardiac Detection

Kailera Therapeutics Secures $600M Series B to Advance Obesity Drug KAI-9531 to Phase 3 Trials

Kailera Therapeutics Launches with $400M to Advance GLP-1 Based Obesity Therapies

Page 1 of 905